Literature DB >> 28533649

Cerebral Toxoplasmosis Masquerading Cns Lymphoma on FDG PET-CT in Post Renal Transplant Patient.

Anirban Mukherjee1, Chandrasekhar Bal1, Madhavi Tripathi1, Chandan Jyoti Das2, Shamim Ahmed Shamim1.   

Abstract

20 year old post renal transplant patient developed recurrent episodes of seizure. MRI revealed focal lesion in right parieto-occipital lobe with perilesional edema. FDG PET-CT revealed multiple hypermetabolic lesions in bilateral cerebral hemisphere. Subsequent biopsy from the lesion demonstrated bradyzoites of Toxoplasma gondii with inflammatory cells and thereby, a confirmatory diagnosis of cerebral toxoplasmosis was made. This case demonstrates the fact that increased FDG uptake in cerebral lesions in post transplant patient should be interpreted with caution and confirmed with histopathological correlation.

Entities:  

Keywords:  FDG PET-CT; cerebral toxoplasmosis; post transplant lymphomatous disorder

Year:  2017        PMID: 28533649      PMCID: PMC5439199          DOI: 10.4103/0972-3919.202254

Source DB:  PubMed          Journal:  Indian J Nucl Med        ISSN: 0974-0244


A 20 year old post renal transplant patient, who was subsequently kept on immunosuppressive therapy, experienced a single episode of seizure after two years of renal transplant. MRI was advised which revealed a focal lesion in the right parieto-occipital lobe (solid arrow) which was hyperintense on both T2 and T1 weighted images with significant perilesional edema [Figure 1]. A differential diagnosis of post transplant lymphoproliferative disorder (PTLD) vs CNS toxoplasmosis was made and patient was referred for 18F- Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (FDG PET-CT) for further evaluation. 18F-FDG PET-CT revealed multiple hypermetabolic enhancing lesions involving left parietal lobe, left parasagittal location and right parieto-occipital lobe [Figure 2]. Maximum Standardised Uptake Value (SUVmax) of the lesion in left parasagittal location was 12.5. All the lesions demonstrated greater uptake than normal brain parenchyma. So, a possible diagnosis of PTLD was made. However, for further confirmation brain biopsy was performed from the right parieto-occipital lobe lesion which demonstrated bradyzoites of Toxoplasma gondii with inflammatory cells and thereby a confirmatory diagnosis of cerebral toxoplasmosis was made. The patient was given anti-toxoplasma therapy with pyrimethamine, sulfadiazine, and folinic acid in combination. Subsequent MRI revealed significant reduction in size of the lesion and perilesional edema [Figure 3].
Figure 1

MRI revealed a focal lesion in the right parieto-occipital lobe which was hyperintense on both T2 and T1 weighted images with significant perilesional edema

Figure 2

18F-FDG PET-CT revealed multiple hypermetabolic enhancing lesions involving left parietal lobe, left parasagittal location and right parieto-occipital lobe

Figure 3

Post treatment MRI revealed significant reduction in size of the lesion and perilesional edema

MRI revealed a focal lesion in the right parieto-occipital lobe which was hyperintense on both T2 and T1 weighted images with significant perilesional edema 18F-FDG PET-CT revealed multiple hypermetabolic enhancing lesions involving left parietal lobe, left parasagittal location and right parieto-occipital lobe Post treatment MRI revealed significant reduction in size of the lesion and perilesional edema Toxoplasma gondii is a protozoan parasite, which causes opportunistic infections in the immunocompromised, as in solid-organ transplant.[12] PTLD is a serious complication of solid organ transplantation with incidence in renal transplant recipients of -1-4%. Central nervous system (CNS) lymphoma is a rare form of PTLD and is more common after renal transplantation.[3] The distinction between primary CNS lymphoma and cerebral toxoplasmosis is important because of difference in the treatment. Cerebral toxoplasmosis can be treated with medication, whereas primary CNS lymphomas are usually treated with radiation therapy and corticosteroids.[4] However, neither CT nor MRI scans can reliably distinguish CNS toxoplasmosis from lymphoma.[5] Several authors reported the usefulness of FDG PET to differentiate cerebral toxoplasmosis from primary CNS lymphoma. Villringer et al.[6] compared FDG uptake within the lesion with the uptake in a contralateral brain area. In all subjects with CNS toxoplasmosis, the FDG uptake ratio was significantly lower than the FDG ratio in patients with lymphoma. Hoffman et al.[7] also reported significant difference between FDG uptake in lymphoma and cerebral toxoplasmosis. Westwood et al.[8] also reported the utility of FDG PET-CT in differentiating CNS toxoplasmosis from PTLD. However, all the above mentioned studies were performed in the settings of HIV infection. Whether similar difference exists in the settings of solid organ transplant is a matter of debate. Furthermore, in contrast to the findings of the above mentioned studies, we have found significant higher uptake in the lesions of CNS toxoplasmosis in a post renal transplant patient. Therefore, increased FDG uptake of the cerebral lesion in patients with solid organ transplant should be interpreted with caution in differentiating CNS toxoplasmosis from PTLD and should be confirmed by histopathological evaluation.

Financial support and sponsorship

Nil

Conflicts of interest

There are no conflicts of interest
  8 in total

1.  FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS.

Authors:  J M Hoffman; H A Waskin; T Schifter; M W Hanson; L Gray; S Rosenfeld; R E Coleman
Journal:  J Nucl Med       Date:  1993-04       Impact factor: 10.057

2.  Brain abscess in solid organ transplant recipients receiving cyclosporine-based immunosuppression.

Authors:  R Selby; C B Ramirez; R Singh; I Kleopoulos; S Kusne; T E Starzl; J Fung
Journal:  Arch Surg       Date:  1997-03

Review 3.  Positron emission tomography in patients suffering from HIV-1 infection.

Authors:  Mike Sathekge; Ingeborg Goethals; Alex Maes; Christophe van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-07       Impact factor: 9.236

4.  Cotrimoxazole for treatment of cerebral toxoplasmosis: an observational cohort study during 1994-2006.

Authors:  Guillaume Béraud; Sandrine Pierre-François; Adeline Foltzer; Sylvie Abel; Bernard Liautaud; Didier Smadja; André Cabié
Journal:  Am J Trop Med Hyg       Date:  2009-04       Impact factor: 2.345

5.  Cerebral Toxoplasmosis in a Patient with AIDS on F-18 FDG PET/CT.

Authors:  Hae Won Kim; Kyoung Sook Won; Byung Wook Choi; Seok Kil Zeon
Journal:  Nucl Med Mol Imaging       Date:  2010-02-26

Review 6.  Prevention of toxoplasmosis in transplant patients.

Authors:  F Derouin; H Pelloux
Journal:  Clin Microbiol Infect       Date:  2008-12       Impact factor: 8.067

7.  Utility of FDG-PETCT and magnetic resonance spectroscopy in differentiating between cerebral lymphoma and non-malignant CNS lesions in HIV-infected patients.

Authors:  Thomas D Westwood; Celia Hogan; Peter J Julyan; Glyn Coutts; Suzie Bonington; Bernadette Carrington; Ben Taylor; Saye Khoo; Alec Bonington
Journal:  Eur J Radiol       Date:  2013-04-08       Impact factor: 3.528

8.  Differential diagnosis of CNS lesions in AIDS patients by FDG-PET.

Authors:  K Villringer; H Jäger; M Dichgans; S Ziegler; J Poppinger; M Herz; C Kruschke; S Minoshima; H W Pfister; M Schwaiger
Journal:  J Comput Assist Tomogr       Date:  1995 Jul-Aug       Impact factor: 1.826

  8 in total
  1 in total

Review 1.  PET-CT in Clinical Adult Oncology-V. Head and Neck and Neuro Oncology.

Authors:  Richard H Wiggins; John M Hoffman; Gabriel C Fine; Matthew F Covington; Ahmed Ebada Salem; Bhasker R Koppula; Kathryn A Morton
Journal:  Cancers (Basel)       Date:  2022-05-31       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.